CA9 and renal cell carcinoma: Recently, cytokine release syndrome and immune cell-associated neurological syndrome have been reported to be toxic to CAR-T, although the incidence of acute kidney injury is relatively low and most patients will recover within 30 days suggesting that the therapeutic impact of CAIX-CAR-T cell therapy on renal cell carcinoma is limited (174).